Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Abstract

Phenyliminoimidazolidines. Characterization of a class of potent agonists of octopamine-sensitive adenylate cyclase and their use in understanding the pharmacology of octopamine receptors.

J A Nathanson
Molecular Pharmacology September 1985, 28 (3) 254-268;
J A Nathanson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Octopamine, a major aminergic neurotransmitter in invertebrates, exerts many of its actions through receptors which are associated with the activation of adenylate cyclase. The present study defines and characterizes a new class of potent octopamine agonists, the substituted phenyliminoimidazolidines (PIIs). Approximately 30 of these derivatives were examined for agonist and antagonist effects on the highly enriched and specific octopamine-sensitive adenylate cyclase present in the firefly light organ, as well as on adenylate cyclases present in other invertebrate and vertebrate tissues. Several derivatives were extremely active and some (e.g. 2,6-diethyl-PII) had potencies exceeding those of any previously described agonists of octopamine-sensitive adenylate cyclase. Stimulation by the potent PIIs was reversible, nonadditive to that caused by octopamine, and could be antagonized by antagonists such as cyproheptadine (Ki = 4 microM), phentolamine (Ki = 23 microM), and propranolol (Ki = 72 microM). These inhibitory constants agreed well with those for inhibiting octopamine stimulation. Certain PII derivatives acted as partial agonists and some as antagonists of octopamine stimulation. Structure-activity relationships revealed, among other things, that short-chain alkyl substitution in the 2- and 6-phenyl positions enhanced activity, as did further substitution of 4-halo, 4-methyl, or 4-hydroxy substituents. 4-Amino or N-alkyl substitution decreased activity. Structurally related benzylimidazoline derivatives such as tolazoline and naphazoline were partial octopamine agonists, generally less active than the PIIs. Comparison, in three invertebrate species, of the effects of the PIIs and two other chemical classes of octopamine agonists demonstrated clearcut differences in species responsiveness. Other comparative studies revealed that the agonist activity of the potent PIIs was specific for tissues containing an octopamine-sensitive adenylate cyclase; adenylate cyclases activated by dopamine or by beta 1- or beta 2-adrenergic agonists were unaffected by these compounds. Evaluation of the relative binding affinities of various PIIs for mammalian alpha-adrenergic receptors, as well as the ability of various antagonists to block PII binding, strongly suggested that the active PIIs are affecting a class of octopamine receptors distinct from mammalian alpha 1- or alpha 2-adrenergic receptors. These octopamine receptors also appeared distinct from mammalian 5-HT1 and 5-HT2 receptors. Correlative physiological studies in insects revealed that the active PIIs mimicked octopamine and were potent activators of light emission in the firefly light organ.(ABSTRACT TRUNCATED AT 400 WORDS)

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology
Vol. 28, Issue 3
1 Sep 1985
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Phenyliminoimidazolidines. Characterization of a class of potent agonists of octopamine-sensitive adenylate cyclase and their use in understanding the pharmacology of octopamine receptors.
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Abstract

Phenyliminoimidazolidines. Characterization of a class of potent agonists of octopamine-sensitive adenylate cyclase and their use in understanding the pharmacology of octopamine receptors.

J A Nathanson
Molecular Pharmacology September 1, 1985, 28 (3) 254-268;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Abstract

Phenyliminoimidazolidines. Characterization of a class of potent agonists of octopamine-sensitive adenylate cyclase and their use in understanding the pharmacology of octopamine receptors.

J A Nathanson
Molecular Pharmacology September 1, 1985, 28 (3) 254-268;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics